Shreehas Tambe is CEO and Managing Director of Biocon Limited, a biopharmaceutical company.

GLP-1 therapies have changed the treatment of type 2 diabetes – but the debate is dominated by promises of weight loss and cost issues.

With the first patent expirations, generics and biosimilar insulins are coming into focus as an opportunity for affordable access and more resilient supply chains. The decisive factor now is whether politicians structurally restructure standard care, writes Shreehas Tambe, CEO and Managing Director of Biocon Limited.

In Germany, around eleven million people live with diabetes, 9.1 million of whom are diagnosed with type 2 diabetes. Another two million are considered undiagnosed. In combination with concomitant cardiometabolic diseases, this burden of disease poses a significant challenge for the health care system. How can medical progress, financial sustainability and equitable access to therapies be ensured at the same time?

In recent years, GLP-1 receptor agonists have fundamentally changed diabetology and the treatment of obesity. In the public debate, the fact that these therapies were originally developed for the treatment of type 2 diabetes and obesity-associated complications is increasingly being overlooked.

This change in perception obscures the actual health policy challenges and the question of how medically necessary GLP-1 therapies can be systematically and responsibly integrated into standard care, taking into account costs, access and security of supply.

Accordingly, the debate should once again focus more strongly on the medical benefits of these therapies and on the structural prerequisites for sustainable care.

Against this background, the first patent expirations and increasing competition are now coming into the picture as central levers for long-term sustainable diabetes care.

A structural turning point: GLP-1 generics and biosimilar insulins

The patent expirations for first-generation GLP-1 molecules open up new competitive space and thus improve patients’ access to medicines. Generic GLP-1 injections for the treatment of type 2 diabetes are already receiving approvals in several countries.

At the same time, oral GLP-1 formulations are gaining in importance. They are easier to manufacture, scale, apply and have the potential to fundamentally change existing care structures. In markets where market exclusivity for GLP-1 molecules has expired, significant price reductions are already showing the potential of competitive dynamics.

However, generic GLP-1 therapies only develop their full effect in conjunction with affordable biosimilar insulins. Together, they enable a cost-effective treatment concept, from early intervention to intensified insulin therapy and at prices that healthcare systems can sustain in the long term. This is a step forward, but it alone does not solve the complex issue of care.

Security of supply as a prerequisite

GLP-1 peptides are significantly more complex and cost-intensive to produce than conventional small molecule drugs and are therefore subject to a natural price floor.

Sustainable access therefore requires a balance: affordability while at the same time providing sufficient incentives for investment in stable and resilient supply chains.

Equally crucial is the diversification of production. Patent protection often leads to a concentration of a few suppliers, so that with the expiration of patents and the market entry of several qualified manufacturers, dependence on individual sources of supply is reduced.

Especially in the case of chronic diseases such as diabetes, where patients are ependent on their medication on a daily basis, this significantly increases the security of supply.

In view of the steadily growing prevalence of obesity and diabetes, alternatives to original preparations can noticeably relieve the burden on health systems. Biosimilars and generics expand the therapeutic spectrum for those affected, while at the same time reducing economic pressure on healthcare budgets and thus contributing to more sustainable security of care for all.

A question of political will?

Patent expirations, generic-induced competition and biosimilar insulins open up a real structural opportunity for German health policy for the first time: the development of a cost-efficient treatment architecture for type 2 diabetes that ranges from early intervention to long-term care.

The current cabinet draft to stabilise the statutory health insurance contribution rates underlines the pressure to act. A structural deficit of up to 40 billion euros is forecast by 2030. Against this background, the systematic integration of GLP-1 generics and biosimilar insulins into a coherent health strategy is no longer optional. Used properly, they can free up resources that can be invested in earlier diagnostics, nutritional support and the next generation of life-changing incretin therapies – central building blocks of sustainable diabetes care.

The focus must be on health policy decisions: reimbursement models that reward long-term medical benefits and a procurement framework that prioritizes resilient, diversified supply chains. Affordable access to effective medicines must remain the foundation of sustainable diabetes care.

Shreehas Tambe is CEO and Managing Director of Biocon Limited, a biopharmaceutical company.

Shreehas Tambe’s OpEd published in Tagesspiegel Background on May 15, 2026: How generics and biosimilars make diabetes care affordable

Leave a Reply